top of page
Image

Thinking
laterally
about CAR-T

Our mission is to develop next generation CAR-T therapies using the Company’s proprietary Lateral CAR platform to improve treatment outcomes and save the lives of patients with refractory cancers

 

​

Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours 

+ read more

​

Latest News

Breakfast
Ideas

5d166a945fd97_edited.jpg

Our Science

Next generation CAR T-cell therapy to revolutionise the technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.

Image
Lateral CAR T-Cell Platform

Founded to translate 20 years of pioneering Chimeric Antigen Receptor T-Cell (CAR-T) research led by Dr John Maher at King's College London (KCL), Leucid Bio has developed a proprietary Lateral CAR platform that builds upon Dr Maher’s novel  novel CAR-T model  in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. This technology gives properties to the CAR-T enabling them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.

CAR T cell.png
Lateral NKG2D CAT-T Candidate - LEU011.png
Image
Lead asset - LEU011

LEU011 is an autologous, lateral CAR-T targeting NKG2D stress ligands. NKG2D ligands are expressed on more than 80% of human tumour cells, positioning LEU011 as a novel CAR-T for the potential treatment of multiple cancers.  

bottom of page